Posted at 06 Jan, 00:00h in News by alic 0 Comments NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program Transformative Acquisition Deepens Pipeline with In-Process Phase 2/3 Clinical Study of Proprietary Oral Formulation of Niclosamide for the Treatment of COVID-19 Tags: ANA Therapeutics ShareNeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program&media=', 'popupwindow', 'scrollbars=yes,width=800,height=400');popUp.focus();return false"> Print page 0 Likes
Sorry, the comment form is closed at this time.